{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T15:01:33Z","timestamp":1769526093972,"version":"3.49.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T00:00:00Z","timestamp":1648166400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Case Reports"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.jaccas.2022.01.027","type":"journal-article","created":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T17:19:44Z","timestamp":1655313584000},"page":"751-754","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Left Atrial Appendage Occlusion as an Alternative to Anticoagulants in Ibrutinib-Induced Hemorrhagic Pericardial Effusion"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9010-3569","authenticated-orcid":false,"given":"Hafiz","family":"Jeelani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Mubbashir","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nayha","family":"Tahir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace","family":"Ying","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonika","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryana","family":"Yaremko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jashan","family":"Gill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.jaccas.2022.01.027_bib1","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","article-title":"Three-year follow-up of treatment-na\u00efve and previously treated patients with CLL and SLL receiving single-agent ibrutinib","volume":"125","author":"Byrd","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jaccas.2022.01.027_bib2","doi-asserted-by":"crossref","first-page":"e768","DOI":"10.1097\/MJT.0000000000000775","article-title":"Cardiovascular side effects of tyrosine kinase inhibitor ibrutinib (imbruvica) and interaction with direct oral anticoagulant","volume":"25","author":"Khalid","year":"2018","journal-title":"Am J Ther"},{"key":"10.1016\/j.jaccas.2022.01.027_bib3","first-page":"4282486","article-title":"Ibrutinib-associated cardiac tamponade with concurrent antiplatelet therapy","volume":"2020","author":"Miatech","year":"2020","journal-title":"Case Rep Hematol"},{"key":"10.1016\/j.jaccas.2022.01.027_bib4","first-page":"A3488","article-title":"Hemorrhagic pericardial effusion an unreported complication of ibrutinib","volume":"199","author":"Patel","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.jaccas.2022.01.027_bib5","first-page":"ytx018","article-title":"Acute haemorrhagic tamponade in cancer patients receiving direct oral anticoagulant: case series","volume":"1","author":"Nassif","year":"2017","journal-title":"Eur Heart J Case Rep"},{"issue":"20","key":"10.1016\/j.jaccas.2022.01.027_bib6","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0960-9822(98)70471-3","article-title":"A\u00a0role for Bruton\u2019s tyrosine kinase (BTK) in platelet activation by collagen","volume":"8","author":"Quek","year":"1998","journal-title":"Curr Biol"},{"issue":"10","key":"10.1016\/j.jaccas.2022.01.027_bib7","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1182\/blood-2003-04-1142","article-title":"Tec regulates platelet activation by GPVI in the absence of BTK","volume":"102","author":"Atkinson","year":"2003","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jaccas.2022.01.027_bib8","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"Agnelli","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccas.2022.01.027_bib9","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s40262-017-0529-1","article-title":"Pharmacokinetic and pharmacodynamic considerations in the treatment of chronic lymphocytic leukemia: ibrutinib, idelalisib, and venetoclax","author":"Waldron","year":"2017","journal-title":"Clin Pharmacokinet"},{"issue":"26","key":"10.1016\/j.jaccas.2022.01.027_bib10","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1182\/blood-2014-06-583294","article-title":"Ibrutinib treatment affects collagen and von Willebrand factor\u2013dependent platelet functions","volume":"124","author":"Levade","year":"2014","journal-title":"Blood"}],"container-title":["JACC: Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666084922002200?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666084922002200?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T18:49:20Z","timestamp":1762973360000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666084922002200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":10,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S2666084922002200"],"URL":"https:\/\/doi.org\/10.1016\/j.jaccas.2022.01.027","relation":{},"ISSN":["2666-0849"],"issn-type":[{"value":"2666-0849","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Left Atrial Appendage Occlusion as an Alternative to Anticoagulants in Ibrutinib-Induced Hemorrhagic Pericardial Effusion","name":"articletitle","label":"Article Title"},{"value":"JACC: Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaccas.2022.01.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}